Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sur1M2
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
Sur1M2 is a **modified peptide derived from survivin (BIRC5)**, a protein highly expressed in many cancers and associated with inhibition of apoptosis. Sur1M2 is designed to act as a cancer vaccine antigen, specifically capable of inducing **CD8+ T-cell responses**. The primary mechanism is the induction of cellular and humoral immune responses directed against survivin-expressing tumor cells, enabling immune-mediated anti-tumor activity. Sur1M2 has been tested both in vitro and in clinical settings for its immunogenic properties and as part of peptide vaccination strategies in metastatic melanoma and other survivin-expressing cancers[2][6][7][10].
- Other names
- survivin Sur1M2 peptide vaccine
02
Targets
Sur1M2-HLA-A2 (Survivin-derived peptide–Major Histocompatibility Complex)BIRC5 (Survivin)
Beyond the preview
Go deeper on Sur1M2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sur1M2.